MannKind | MNKD - Current Liabilities


MannKind reported $142.9M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Adma Biologics USD 75.76M 2.22M Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Halozyme Therapeutics USD 344.44M 18.77M Jun/2026
Insmed USD 438.74M 77.74M Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
MacroGenics USD 108.82M 12.88M Jun/2026
MannKind USD 142.9M 8.34M Jun/2026
Merck USD 27.73B 786M Jun/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Novavax USD 330.57M 11.89M Jun/2026
Novo Nordisk DKK 36.54B 188.62B Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Xencor USD 81.86M 8.41M Jun/2026